|
Q3 FY2026
As of Apr 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
Q2 FY2023
As of Jan 31, 2023
|
Q1 FY2023
As of Oct 31, 2022
|
Q4 FY2022
As of Jul 31, 2022
|
Q3 FY2022
As of Apr 30, 2022
|
Q2 FY2022
As of Jan 31, 2022
|
Q1 FY2022
As of Oct 31, 2021
|
Q4 FY2021
As of Jul 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | ||||||||||||||||||||
| Accrued interest income | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Loan receivable | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Homes inventory for sales | ||||||||||||||||||||
| Due from related party | ||||||||||||||||||||
| Current assets associated with discontinued operations | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Construction in progress | ||||||||||||||||||||
| Investment | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Deferred rent income | ||||||||||||||||||||
| Rent deposit payable | ||||||||||||||||||||
| Loan payable - current portion | ||||||||||||||||||||
| Loans payable, related party | ||||||||||||||||||||
| Bank borrowings - current portion, net | ||||||||||||||||||||
| Due to related parties | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Current liabilities associated with discontinued operations | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Bank borrowings, net | ||||||||||||||||||||
| Bank borrowings, net | ||||||||||||||||||||
| Loan payable | ||||||||||||||||||||
| Non-current liabilities associated with discontinued operations | ||||||||||||||||||||
| Promissory note-related party | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Preferred stock value | ||||||||||||||||||||
| Preferred Stocks | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Total preferred stock value | ||||||||||||||||||||
| Common stock: 300,000,000 authorized; $0.001 par value 17,926,686 shares and 16,276,686 shares issued and outstanding at April 30, 2026, and July 31, 2025, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Deficit attributable to noncontrolling interests-discontinued operations | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...